Immunome (NASDAQ:IMNM) Stock Moved Up to Sell by Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Immunome (NASDAQ:IMNM – Free Report) from a strong sell rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

A number of other research firms have also issued reports on IMNM. Wedbush increased their price target on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Citigroup reaffirmed a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Alliance Global Partners initiated coverage on shares of Immunome in a research report on Monday, September 21st. They set a “buy” rating and a $32.00 price objective on the stock. Truist Financial upped their price objective on shares of Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Immunome in a research report on Thursday, September 10th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $35.18.

Read Our Latest Stock Report on Immunome

Immunome Trading Down 4.2%

NASDAQ:IMNM opened at $21.41 on Friday. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of -8.46 and a beta of 2.13. Immunome has a 1-year low of $10.06 and a 1-year high of $30.06. The business’s fifty day moving average price is $25.45 and its 200 day moving average price is $22.85.

Immunome (NASDAQ:IMNM – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). Equities analysts forecast that Immunome will post -2.38 earnings per share for the current year.

Insider Transactions at Immunome

In other Immunome news, insider Robert Lechleider sold 55,000 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total value of $1,244,100.00. Following the transaction, the insider directly owned 15,805 shares of the company’s stock, valued at $357,509.10. This represents a 77.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 13,200 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the sale, the insider directly owned 65,050 shares of the company’s stock, valued at $1,647,066. This trade represents a 16.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 580,510 shares of company stock worth $13,824,240. 7.21% of the stock is owned by company insiders.

Hedge Funds Weigh In On Immunome

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMNM. BlackRock Inc. acquired a new stake in Immunome in the second quarter valued at approximately $186,588,000. Wellington Management Group LLP increased its stake in shares of Immunome by 10.1% during the 2nd quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company’s stock worth $110,404,000 after purchasing an additional 478,239 shares during the last quarter. Primecap Management Co. CA bought a new position in shares of Immunome during the 2nd quarter valued at $97,081,000. Sofinnova Investments Inc. raised its holdings in shares of Immunome by 271.2% during the 4th quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock valued at $34,765,000 after purchasing an additional 1,182,426 shares in the last quarter. Finally, Readystate Asset Management LP raised its holdings in shares of Immunome by 23.3% during the 2nd quarter. Readystate Asset Management LP now owns 1,605,820 shares of the company’s stock valued at $34,027,000 after purchasing an additional 303,958 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

About Immunome

(Get Free Report)

Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development.

Immunome’s activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases.

Featured Stories